Inflammatory cystoid macular edema

Abstract

This review summarizes current thoughts on inflammatory cystoid macular edema focusing on the new, clinically relevant findings. Upcoming data on aqueous constituents in cystoid macular edema and imaging with the new generation of optic coherence tomography offer the hope that a better treatment strategy will soon be established.

Intravitreal VEGF levels in uveitis patients and treatment of uveitic macular oedema with intravitreal bevacizumab

“…18 All patients were informed of potential benefits and side effects. The experimental nature of analyses was approved by the local ethics commission.…”

Topical dexamethasone–cyclodextrin microparticle eye drops for uveitic macular oedema

“…If the hypothesis is proved to be correct, it may be helpful to design more efficient strategies to prevent and manage CSCR. Editor, C ystoid macular oedema (CME) is the main cause of visual loss in patients with uveitis (Rothova 2007). The mainstay of treatment of uveitic CME is corticosteroids and to be effective, steroid needs to be given periocularly, intravitreally or systemically.…”

Vitreous levels of somatostatin in patients with chronic uveitic macular oedema

“…The release and diffusion of cytokines may have a predominant role in the first scenario, but the exact factors and events responsible for the development of chronic macular oedema without active inflammation have not yet been identified. 2 Somatostatin (SST) is a ubiquitous hormone that was initially identified as an inhibitory factor on the growth hormone axis. 3 SST and its receptors are expressed in the uvea, retinal pigment epithelium (RPE) and neuroretina, and the receptors are expressed in the vascular endothelium.…”